PE20090245A1 - Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos - Google Patents

Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos

Info

Publication number
PE20090245A1
PE20090245A1 PE2008000796A PE2008000796A PE20090245A1 PE 20090245 A1 PE20090245 A1 PE 20090245A1 PE 2008000796 A PE2008000796 A PE 2008000796A PE 2008000796 A PE2008000796 A PE 2008000796A PE 20090245 A1 PE20090245 A1 PE 20090245A1
Authority
PE
Peru
Prior art keywords
muc16
antibodies
antibody
cysteine
designed
Prior art date
Application number
PE2008000796A
Other languages
English (en)
Spanish (es)
Inventor
Jagath R Junutula
William Mallet
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20090245A1 publication Critical patent/PE20090245A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2008000796A 2007-05-08 2008-05-07 Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos PE20090245A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91665707P 2007-05-08 2007-05-08

Publications (1)

Publication Number Publication Date
PE20090245A1 true PE20090245A1 (es) 2009-03-17

Family

ID=39789637

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000796A PE20090245A1 (es) 2007-05-08 2008-05-07 Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos

Country Status (11)

Country Link
US (2) US7723485B2 (cg-RX-API-DMAC7.html)
EP (1) EP2144628B1 (cg-RX-API-DMAC7.html)
JP (1) JP5290276B2 (cg-RX-API-DMAC7.html)
CN (1) CN101687037B (cg-RX-API-DMAC7.html)
AR (1) AR066476A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008251608B2 (cg-RX-API-DMAC7.html)
CA (1) CA2683568A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008001334A1 (cg-RX-API-DMAC7.html)
PE (1) PE20090245A1 (cg-RX-API-DMAC7.html)
TW (1) TW200902554A (cg-RX-API-DMAC7.html)
WO (1) WO2008141044A2 (cg-RX-API-DMAC7.html)

Families Citing this family (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
USRE47223E1 (en) * 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
MX2010003718A (es) 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
RU2523419C2 (ru) 2008-07-15 2014-07-20 Дженетек, Инк. Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений
US8623828B2 (en) 2008-12-05 2014-01-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Blocking mesothelin peptide fragments
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2400992B1 (en) 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
SG177653A1 (en) 2009-07-15 2012-02-28 Aimm Therapeutics Bv Gram-positive bacteria specific binding compounds
EP2554669B1 (en) 2010-03-26 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Novel antibody having modification site introduced therein, and antibody fragment
EP3222632A1 (en) 2010-03-26 2017-09-27 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
RS52983B (sr) 2010-04-15 2014-02-28 Spirogen Sárl Pirolobenzodiazepini i njihovi konjugati
CN119552249A (zh) * 2010-06-08 2025-03-04 基因泰克公司 半胱氨酸改造的抗体和偶联物
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
KR20140014116A (ko) 2010-12-20 2014-02-05 제넨테크, 인크. 항-메소텔린 항체 및 면역접합체
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
RS58620B1 (sr) 2011-02-15 2019-05-31 Immunogen Inc Metodi pripremanja konjugata
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
SI2750713T1 (sl) 2011-10-14 2016-01-29 Medimmune Limited Pirolobenzodiazepini in njihovi konjugati
WO2013060867A2 (en) * 2011-10-27 2013-05-02 Genmab A/S Production of heterodimeric proteins
ES3033729T3 (en) 2011-10-28 2025-08-07 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP2015505537A (ja) 2012-01-20 2015-02-23 シー レーン バイオテクノロジーズ， エルエルシー 結合分子コンジュゲート
EP2818480B1 (en) * 2012-02-24 2020-08-26 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
PT3470086T (pt) 2012-10-12 2021-02-01 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
KR101995621B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항-cd22 항체 컨주게이트
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2839860B1 (en) * 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
WO2014057072A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
BR112015014669B1 (pt) 2012-12-21 2023-09-26 Medimmune Limited Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
CN103933575B (zh) 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
AU2014214751B2 (en) * 2013-02-08 2017-06-01 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
US9968687B2 (en) 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JOP20140049B1 (ar) * 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
WO2014164534A2 (en) 2013-03-11 2014-10-09 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
BR112015023070B1 (pt) 2013-03-13 2022-06-07 Genentech, Inc. Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
KR102306490B1 (ko) 2013-03-15 2021-09-28 리제너론 파아마슈티컬스, 인크. 생물학적 활성 분자, 그의 접합체 및 치료 용도
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
PT3677591T (pt) 2013-04-29 2023-02-17 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
BR112015029754A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos anti-teicoico da parede e conjugados
EP3381939A1 (en) 2013-05-31 2018-10-03 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
KR101641206B1 (ko) 2013-06-24 2016-07-22 에이비엘바이오 주식회사 안정성이 개선된 항체-약물 결합체 및 이의 용도
CN105452293B (zh) * 2013-07-03 2021-03-16 首尔大学校产学协力团 转化为半胱氨酸的鸡抗体和使用其的位点特异性缀合
CN105358985B (zh) * 2013-07-09 2018-08-28 内布拉斯加大学董事会 靶向糖蛋白以治疗癌症的新方法
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
EP3038624B1 (en) 2013-08-26 2024-09-25 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
BR112016004242A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
CA2928671A1 (en) 2013-11-06 2015-05-14 Stemcentrx, Inc. Novel anti-claudin antibodies and methods of use
KR101936697B1 (ko) 2013-11-19 2019-01-10 레메젠 리미티드 항-her2 항체 및 이의 접합체
EP3080607A4 (en) 2013-12-12 2017-07-12 AbbVie Stemcentrx LLC Novel anti-dpep3 antibodies and methods of use
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
EP3082875B1 (en) 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
EP3082874A2 (en) 2013-12-16 2016-10-26 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
AU2015218633A1 (en) 2014-02-21 2016-09-01 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
CN104672330A (zh) * 2014-03-11 2015-06-03 南京任诺药业有限公司 用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-N267C
CN104788566A (zh) * 2014-03-11 2015-07-22 南京任诺药业有限公司 用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-V280C
RS64072B1 (sr) 2014-03-19 2023-04-28 Genzyme Corp Mesto-specifični glikoinženjering ciljnih delova
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
RS61379B1 (sr) 2014-04-25 2021-02-26 Pf Medicament Antitelo na igf-1r i njegova upotreba kao usmerenog nosioca za lečenje kancera
RU2685259C2 (ru) 2014-04-25 2019-04-17 Пьер Фабр Медикамент Конъюгат антитела и лекарственного средства и его применение для лечения рака
MY186711A (en) 2014-04-25 2021-08-12 Pf Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
CN106536540A (zh) 2014-07-24 2017-03-22 基因泰克公司 将试剂缀合至含有至少一个三硫键的蛋白质中的巯基部分的方法
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
RU2727663C2 (ru) 2014-09-17 2020-07-22 Дженентек, Инк. Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
US20160074527A1 (en) 2014-09-17 2016-03-17 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
PL3204425T3 (pl) 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
US10617670B2 (en) * 2014-10-10 2020-04-14 Pfizer Inc. Synergistic auristatin combinations
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
WO2016083468A1 (en) 2014-11-25 2016-06-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090040A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
BR112017011325A2 (pt) * 2014-12-03 2020-07-21 Genentech, Inc. ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
CA2970155A1 (en) * 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
JP2018502839A (ja) * 2014-12-09 2018-02-01 アッヴィ・インコーポレイテッド Ｂｃｌ−ｘＬ阻害性化合物およびこれを含む抗体薬物コンジュゲート
EP3233910B1 (en) * 2014-12-19 2019-12-11 Ablynx N.V. Cysteine linked nanobody dimers
EP4592311A2 (en) 2015-02-16 2025-07-30 Lonza Ltd Antibodies
IL296062A (en) 2015-03-17 2022-10-01 Memorial Sloan Kettering Cancer Center Antibodies against muc16 and their uses
SG11201707148PA (en) 2015-03-27 2017-10-30 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
CN108260357A (zh) 2015-04-10 2018-07-06 托马斯杰弗逊大学 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
WO2016205176A1 (en) * 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
CA3002765C (en) 2015-10-26 2023-02-28 Pierre Fabre Medicament Composition for the treatment of igf-1r expressing cancer
US9669106B2 (en) 2015-10-26 2017-06-06 Pierre Fabre Medicament Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer
JP2019505575A (ja) 2015-12-21 2019-02-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 部位特異的な結合のための変異型抗体
JP7088454B2 (ja) * 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
PH12018501589B1 (en) 2016-01-25 2022-08-10 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
BR112018016461A2 (pt) * 2016-02-12 2019-10-01 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
WO2017152083A1 (en) 2016-03-04 2017-09-08 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate
WO2017165734A1 (en) 2016-03-25 2017-09-28 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3442979A4 (en) 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey topoisomerase poisons
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
TWI823836B (zh) * 2016-07-08 2023-12-01 美商建南德克公司 人類副睪蛋白４（ｈｅ４）用於評定癌症治療反應性之用途
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
KR20230041834A (ko) * 2016-08-16 2023-03-24 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
PL3515946T3 (pl) * 2016-09-23 2022-11-07 Regeneron Pharmaceuticals, Inc. Przeciwciała anty-muc16 (mucyna 16)
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
CN118846112A (zh) * 2016-10-08 2024-10-29 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物及其制备方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018086139A1 (en) 2016-11-14 2018-05-17 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
EP3580234A1 (en) * 2017-02-08 2019-12-18 Pfizer Inc. Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
BR112019016420A2 (pt) 2017-02-08 2020-04-07 Adc Therapeutics Sa conjugados pirrolobenzodiazepina-anticorpo
PL3544636T3 (pl) 2017-02-08 2021-12-06 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
PL3612234T3 (pl) 2017-04-20 2024-09-02 Adc Therapeutics Sa Terapia skojarzona z koniugatem anty-AXL przeciwciało-lek
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US11666657B2 (en) * 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
SG11202007919RA (en) * 2017-06-19 2020-09-29 Sichuan Baili Pharm Co Ltd Antibody-drug conjugate having acidic self-stabilization junction
CA3098491A1 (en) * 2017-06-20 2018-12-27 Sichuan Baili Pharm Co. Ltd Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
SI3661562T1 (sl) * 2017-08-04 2025-01-31 Amgen Inc. Postopek konjugiranja CYS-MABS
SMT202200225T1 (it) 2017-08-18 2022-07-21 Medimmune Ltd Coniugati di pirrolobenzodiazepina
CN107583058B (zh) * 2017-09-20 2020-09-18 厉保秋 一种t-2毒素-抗体缀合物及其用途
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
CA3081925A1 (en) * 2017-11-18 2019-05-23 Nzola DE MAGALHAES Product and process for employing gc7 (n1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy
CN110133271B (zh) * 2018-02-09 2022-12-13 北京豪迈生物工程股份有限公司 一种将抗体或其抗原结合片段共价结合至颗粒表面的方法
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN108714220B (zh) * 2018-04-24 2021-11-19 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108727498B (zh) * 2018-04-24 2021-11-26 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108743966B (zh) * 2018-04-24 2021-10-19 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108727499B (zh) * 2018-04-24 2021-12-31 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
EP3802615A4 (en) 2018-06-04 2022-04-13 Precigen, Inc. Muc16 specific chimeric antigen receptors and uses thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7526721B2 (ja) 2018-09-11 2024-08-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 癌治療のためのブロモドメインＢＲＤ４阻害剤としてのｔｅｒｔ－ブチル（Ｓ）－２－（４－（フェニル）－６Ｈ－チエノ［３，２－ｆ］［１，２，４］トリアゾロ［４，３－ａ］［１，４］ジアゼピン－６－イル）アセテート誘導体及び関連化合物
AU2019361281A1 (en) 2018-10-19 2021-04-29 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20210081350A (ko) 2018-10-19 2021-07-01 메드임뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
CN113423730B (zh) 2019-02-15 2024-01-05 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
AU2020242747B2 (en) 2019-03-15 2025-09-18 Medimmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
KR20240104214A (ko) 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
CN113939534B (zh) 2019-04-03 2025-02-28 建新公司 具有降低的断裂的抗αβTCR结合多肽
CN111825742B (zh) * 2019-04-18 2024-01-30 陈铭 Ctpa作为特种偶合剂用于氨基酸离子液体的多肽固相合成
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
TW202112752A (zh) 2019-06-13 2021-04-01 美商博特生物治療公司 胺基苯并氮呯化合物、免疫接合物及其用途
KR20220029725A (ko) 2019-06-29 2022-03-08 항저우 디에이씨 바이오테크 씨오, 엘티디 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법
CN114630684A (zh) 2019-09-03 2022-06-14 博尔特生物治疗药物有限公司 氨基喹啉化合物、免疫缀合物及其用途
AU2020359446A1 (en) 2019-09-30 2022-04-21 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022004875A (es) 2019-10-25 2022-06-17 Bolt Biotherapeutics Inc Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
WO2021080608A1 (en) 2019-10-25 2021-04-29 Medimmune, Llc Branched moiety for use in conjugates
CN110922476A (zh) * 2019-12-16 2020-03-27 蓝怡科技集团股份有限公司 一种生物素偶联抗体及其制备方法和应用
JP2023511184A (ja) 2020-01-22 2023-03-16 メドイミューン・リミテッド 化合物及びその複合体
TW202140076A (zh) 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
CN115996756A (zh) 2020-05-08 2023-04-21 博尔特生物治疗药物有限公司 弹性蛋白酶底物肽连接子免疫缀合物及其用途
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CA3186059A1 (en) 2020-08-13 2022-02-17 Romas Kudirka Pyrazoloazepine immunoconjugates, and uses thereof
AU2021337687A1 (en) 2020-09-04 2023-03-23 CSPC Megalith Biopharmaceutical Co., Ltd., Nectin-4 antibodies and uses thereof
CN116829592A (zh) 2020-09-11 2023-09-29 免疫医疗有限公司 治疗性b7-h4结合分子
AU2021398552A1 (en) 2020-12-11 2023-06-29 Bolt Biotherapeutics, Inc. Anti-pd-l1 immunoconjugates, and uses thereof
CN116897054A (zh) 2020-12-11 2023-10-17 博尔特生物治疗药物有限公司 抗her2免疫缀合物及其用途
CN116744978A (zh) 2020-12-11 2023-09-12 博尔特生物治疗药物有限公司 抗her2免疫缀合物及其用途
CA3200051A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-cea immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
US20240299569A1 (en) 2021-03-26 2024-09-12 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
US20240197899A1 (en) 2021-03-26 2024-06-20 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX2023012277A (es) * 2021-04-16 2023-12-07 Novartis Ag Conjugados anticuerpo-fármaco y métodos para fabricar los mismos.
JP2024539993A (ja) 2021-10-29 2024-10-31 ボルト バイオセラピューティクス、インコーポレーテッド システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役
CA3237211A1 (en) 2021-11-10 2023-05-19 Astrazeneca Ab Antibody molecules and conjugates
WO2023088963A1 (en) 2021-11-19 2023-05-25 Adc Therapeutics Sa Anti-il-13ralpha2 conjugates
US20230201366A1 (en) 2021-11-19 2023-06-29 Adc Therapeutics Sa Anti-psma conjugates
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
EP4230222A1 (en) 2022-02-17 2023-08-23 Oxsonics Limited Combination therapy with an anti-axl antibody-pbd conjugate and nanocups
IL315178A (en) 2022-02-28 2024-10-01 Adc Therapeutics Sa Dosage regimen
IL315308A (en) 2022-03-09 2024-10-01 Astrazeneca Ab Binding molecules against frα
US20250177550A1 (en) 2022-03-11 2025-06-05 Astrazeneca Ab A scoring method for an anti-fr alpha antibody drug conjugate therapy
KR20250029133A (ko) 2022-06-27 2025-03-04 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
EP4583919A1 (en) 2022-09-09 2025-07-16 MyricX Pharma Limited Antibody drug conjugate comprising nmt inhibitor and its use
KR20250099224A (ko) 2022-11-01 2025-07-01 하이델베르크 파마 리서치 게엠베하 항-gucy2c 항체 및 이의 용도
WO2024129756A1 (en) * 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
AU2023393382A1 (en) 2022-12-14 2025-06-19 Pheon Therapeutics Ltd Cytotoxic compounds
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
TW202432187A (zh) 2022-12-23 2024-08-16 美商建南德克公司 小腦蛋白降解劑結合物及其用途
EP4410314A1 (en) 2023-02-02 2024-08-07 ADC Therapeutics SA Combination therapy comprising anti-cd22 antibody-drug conjugate and irak1 inhibitor
EP4665404A1 (en) 2023-02-14 2025-12-24 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
IL322687A (en) 2023-02-16 2025-10-01 Astrazeneca Ab Combination therapies for cancer treatment with therapeutic binding molecules
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment
WO2024223899A1 (en) 2023-04-28 2024-10-31 Medimmune Limited B7-h4 therapeutic binding molecules for the treatment of cancer
WO2025083061A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-napi2b conjugates
WO2025083064A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-asct2 conjugates
WO2025083067A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-claudin-6 conjugates
EP4548936A1 (en) * 2023-10-30 2025-05-07 BioNTech SE Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
WO2025109097A2 (en) 2023-11-24 2025-05-30 Heidelberg Pharma Research Gmbh Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereof
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
WO2025120040A1 (en) 2023-12-06 2025-06-12 Adc Therapeutics Sa Anti-psma antibody drug conjugates comprising exatecan
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
EP4596569A1 (en) * 2024-02-05 2025-08-06 Syndivia Site specific antibody drug conjugates and their process of preparation
GB202403391D0 (en) 2024-03-08 2024-04-24 Myricx Pharma Ltd Novel compounds and their use in therapy
GB202405758D0 (en) 2024-04-24 2024-06-05 King S College London Compounds
GB202407700D0 (en) 2024-05-30 2024-07-17 Francis Crick Institute Ltd F-actin binding agents

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1995009864A1 (en) 1993-10-01 1995-04-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
SI1325932T1 (cg-RX-API-DMAC7.html) 1997-04-07 2005-08-31 Genentech Inc
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2002092836A2 (en) 2001-05-11 2002-11-21 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
EP1482972A4 (en) 2001-11-20 2005-11-23 Seattle Genetics Inc TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
US7935338B2 (en) 2001-12-11 2011-05-03 University Of Massachusetts Antibodies to treat cancer
WO2004000547A1 (en) 2002-06-21 2003-12-31 Boler Lewyn B Jr Device and system for coating a surface
US7202346B2 (en) 2002-07-03 2007-04-10 Immunogen Inc. Antibodies to non-shed Muc1 and Muc16, and uses thereof
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7429382B2 (en) 2002-10-16 2008-09-30 Corixa Corporation Antibodies that bind cell-associated CA 125/O772P and methods of use thereof
AU2003294355A1 (en) 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
ES2690079T3 (es) * 2004-09-03 2018-11-19 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
US8404803B2 (en) 2005-03-31 2013-03-26 Chugai Seiyaku Kabushiki Kaisha Cancer-associated antigen analogue peptides and uses thereof
PL2135881T3 (pl) 2005-06-20 2012-02-29 Genentech Inc Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.

Also Published As

Publication number Publication date
EP2144628B1 (en) 2012-10-17
EP2144628A2 (en) 2010-01-20
CN101687037B (zh) 2013-07-10
AU2008251608B2 (en) 2014-03-27
CA2683568A1 (en) 2008-11-20
WO2008141044A2 (en) 2008-11-20
CL2008001334A1 (es) 2008-09-22
TW200902554A (en) 2009-01-16
US20080311134A1 (en) 2008-12-18
AR066476A1 (es) 2009-08-19
US7723485B2 (en) 2010-05-25
AU2008251608A1 (en) 2008-11-20
JP5290276B2 (ja) 2013-09-18
USRE47194E1 (en) 2019-01-08
WO2008141044A3 (en) 2008-12-31
CN101687037A (zh) 2010-03-31
JP2010526821A (ja) 2010-08-05

Similar Documents

Publication Publication Date Title
PE20090245A1 (es) Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
CO2019004955A2 (es) Anticuerpos anti-met, moleculas de unión a antígeno bispecificas que se unen a met y métodos de uso de los mismos
AR096015A1 (es) Conjugados de fármacos con anticuerpos
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
PE20181399A1 (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica
AR107787A1 (es) Conjugados de anticuerpos basados en eribulina y métodos de uso
AR095666A1 (es) Conjugados de fármacos con anticuerpos
PE20140573A1 (es) Conjugados de anticuerpo-farmaco
ECSP19044625A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
PE20140833A1 (es) Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
DOP2013000219A (es) Anticuerpos imitadores de receptores de celulas t especificos para peptido wt1 unido a hla-a2
PE20170517A1 (es) Conjugados de anticuerpo-farmaco-anti-ptk7
EA201300016A1 (ru) Конъюгаты антител человека против тканевого фактора с лекарственными препаратами
MX2020011554A (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19).
PE20170917A1 (es) Anticuerpos anti-mesotelina e inmunoconjugados
HN2011002834A (es) Inmunoconjugados de antimesotelina y usos de los mismos
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
CL2018000131A1 (es) Inmunoconjugados de il22
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
PE20211296A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos

Legal Events

Date Code Title Description
FD Application declared void or lapsed